Evidence map›Paper›PMID 38593222›Full record

ArticleBlood advances2024

Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort.

Shermarke Hassan, Guido Baselli, Luca Mollica, Riccardo L Rossi, Himani Chand, Amal El-Beshlawy, Mohsen Elalfy, Vijay Ramanan, Peyman Eshghi, Mehran Karimi and 3 more

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Shaping hemophilia care: lessons and legacy of the SIPPET trial after 10 years.Research and practice in thrombosis and haemostasis · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shermarke HassanDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0002-5045-636X
Guido BaselliDepartment of Transfusion Medicine and Hematology, Translational Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0000-0002-0234-6828
Luca MollicaDepartment of Medical Biotechnologies and Translational Medicine, LITA/University of Milan, Milan, Italy.ORCID 0000-0001-8164-7663
Riccardo L RossiBioinformatics, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi," Milan, Italy.ORCID 0000-0002-4964-3264
Himani ChandDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Amal El-BeshlawyPediatric Hematology Department, Cairo University Pediatric Hospital, Cairo, Egypt.
Mohsen ElalfyFaculty of Medicine, Ain Shams University, Department of Pediatrics, Cairo, Egypt.
Vijay RamananDepartment of Hematology, Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
Peyman EshghiCongenital Pediatric Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mehran KarimiPediatric Hematology-Oncology Department, American Hospital Dubai, Dubai, United Arab Emirates.ORCID 0000-0001-8555-1001
Roberta PallaDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Frits R RosendaalDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-2558-7496
Flora PeyvandiDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0001-7423-9864

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractInhibitor development is the most severe complication of hemophilia A (HA) care and is associated with increased morbidity and mortality. This study aimed to use a novel immunoglobulin G epitope mapping method to explore the factor VIII (FVIII)-specific epitope profile in the SIPPET cohort population and to develop an epitope mapping-based inhibitor prediction model. The population consisted of 122 previously untreated patients with severe HA who were followed up for 50 days of exposure to FVIII or 3 years, whichever occurred first. Sampling was performed before FVIII treatment and at the end of the follow-up. The outcome was inhibitor development. The FVIII epitope repertoire was assessed by means of a novel random peptide phage-display assay. A least absolute shrinkage and selection operator (LASSO) regression model and a random forest model were fitted on posttreatment sample data and validated in pretreatment sample data. The predictive performance of these models was assessed by the C-statistic and a calibration plot. We identified 27 775 peptides putatively directed against FVIII, which were used as input for the statistical models. The C-statistic of the LASSO and random forest models were good at 0.78 (95% confidence interval [CI], 0.69-0.86) and 0.80 (95% CI, 0.72-0.89). Model calibration of both models was moderately good. Two statistical models, developed on data from a novel random peptide phage display assay, were used to predict inhibitor development before exposure to exogenous FVIII. These models can be used to set up diagnostic tests that predict the risk of inhibitor development before starting treatment with FVIII.

Indexed as

Factor VIIIHemophilia APeptide LibraryCohort StudiesEpitope MappingEpitopesHumansMaleEpitopesFactor VIIIPeptide Library

Identifiers

PMID38593222
PMCPMC11176960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.